Quentin J Sattentau

List of Publications by Year
in descending order

108 papers	10,409 citations	34016 52 h-index	33814 99 g-index
117 all docs	117 docs citations	117 times ranked	9798 citing authors

#	Article	IF	Citations
1	High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers. Npj Vaccines, 2022, 7, 27.	2.9	13
2	Glycans in HIV-1 vaccine design â€“ engaging the shield. Trends in Microbiology, 2022, 30, 866-881.	3.5	7
3	Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses. Frontiers in Immunology, 2022, 13, 882972.	2.2	32
4	Shared sugars â€“ parasite glycan homology in HIV-1 vaccine design. Trends in Parasitology, 2022, , .	1.5	0
5	Pathogen-sugar interactions revealed by universal saturation transfer analysis. Science, 2022, 377, .	6.0	24
6	Augmenting the Immune Response against a Stabilized HIV-1 Clade C Envelope Trimer by Silica Nanoparticle Delivery. Vaccines, 2021, 9, 642.	2.1	9
7	Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization. Science Advances, 2021, 7, .	4.7	37
8	Stepwise Conformational Stabilization of a HIV-1 Clade C Consensus Envelope Trimer Immunogen Impacts the Profile of Vaccine-Induced Antibody Responses. Vaccines, 2021, 9, 750.	2.1	11
9	Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers. Npj Vaccines, 2021, 6, 103.	2.9	8
10	Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. Science Advances, 2021, 7, eabg7996.	4.7	20
11	Human MAIT cells respond to and suppress HIV-1. ELife, 2021, 10, .	2.8	14
12	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. PLoS Pathogens, 2019, 15, e1008026.	2.1	56
13	HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. PLoS Pathogens, 2018, 14, e1007431.	2.1	36
14	Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. PLoS Pathogens, 2018, 14, e1006986.	2.1	28
15	RNA Helicase DDX1 Converts RNA G-Quadruplex Structures into R-Loops to Promote IgH Class Switch Recombination. Molecular Cell, 2018, 70, 650-662.e8.	4.5	133
16	Astrocytes Resist HIV-1 Fusion but Engulf Infected Macrophage Material. Cell Reports, 2017, 18, 1473-1483.	2.9	73
17	Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. Current Opinion in HIV and AIDS, 2017, 12, 241-249.	1.5	43
18	Efferocytosis of Pathogen-Infected Cells. Frontiers in Immunology, 2017, 8, 1863.	2.2	37

#	Article	IF	Citations
19	HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. PLoS ONE, 2017, 12, e0181886.	1.1	16
20	Nasal Immunization Confers High Avidity Neutralizing Antibody Response and Immunity to Primary and Recurrent Genital Herpes in Guinea Pigs. Frontiers in Immunology, 2016, 7, 640.	2.2	9
21	Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens. Journal of Virology, 2016, 90, 813-828.	1.5	34
22	Sterile inflammation induced by Carbopol elicits robust adaptive immune responses in the absence of pathogen-associated molecular patterns. Vaccine, 2016, 34, 2188-2196.	1.7	18
23	Macrophages and HIV-1: An Unhealthy Constellation. Cell Host and Microbe, 2016, 19, 304-310.	5.1	140
24	The autophagy gene Atg16l1 differentially regulates Treg and TH2 cells to control intestinal inflammation. ELife, 2016, 5, e12444.	2.8	153
25	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell, 2015, 161, 1280-1292.	13.5	305
26	The Carbomer-Lecithin Adjuvant Adjuplex Has Potent Immunoactivating Properties and Elicits Protective Adaptive Immunity against Influenza Virus Challenge in Mice. Vaccine Journal, 2015, 22, 1004-1012.	3.2	37
27	Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: Complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine, 2015, 33, 2086-2095.	1.7	63
28	High-Multiplicity HIV-1 Infection and Neutralizing Antibody Evasion Mediated by the Macrophage-T Cell Virological Synapse. Journal of Virology, 2014, 88, 2025-2034.	1.5	98
29	Macrophage Infection via Selective Capture of HIV-1-Infected CD4+ T Cells. Cell Host and Microbe, 2014, 16, 711-721.	5.1	143
30	Dry roasting enhances peanut-induced allergic sensitization across mucosal and cutaneous routes in mice. Journal of Allergy and Clinical Immunology, 2014, 134, 1453-1456.	1.5	41
31	Immunogen design to focus the B-cell repertoire. Current Opinion in HIV and AIDS, 2014, 9, 217-223.	1.5	13
32	Refocussing Antibody Responses by Chemical Modification of Vaccine Antigens. AIDS Research and Human Retroviruses, 2014, 30, A66-A67.	0.5	0
33	Polyethyleneimine is a potent systemic adjuvant for glycoprotein antigens. International Immunology, 2014, 26, 531-538.	1.8	61
34	Comparison of Neutralizing Antibody Responses Elicited from Highly Diverse Polyvalent Heterotrimeric HIV-1 gp140 Cocktail Immunogens versus a Monovalent Counterpart in Rhesus Macaques. PLoS ONE, 2014, 9, e114709.	1.1	11
35	Development of prophylactic vaccines against HIV-1. Retrovirology, 2013, 10, 72.	0.9	64
36	Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies. Vaccine, 2013, 31, 5789-5797.	1.7	71

#	Article	IF	Citations
37	Multiple proviral integration events after virological synapse-mediated HIV-1 spread. Virology, 2013, 443, 143-149.	1.1	45
38	The HIV-1-containing macrophage compartment: a perfect cellular niche?. Trends in Microbiology, 2013, 21, 405-412.	3.5	82
39	High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacy. Aids, 2013, 27, 2201-2206.	1.0	65
40	Anti-HIV IgA isotypes. Aids, 2013, 27, F13-F20.	1.0	114
41	Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens. Vaccines, 2013, 1, 497-512.	2.1	15
42	Mixed Adjuvant Formulations Reveal a New Combination That Elicit Antibody Response Comparable to Freund's Adjuvants. PLoS ONE, 2012, 7, e35083.	1.1	44
43	Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nature Biotechnology, 2012, 30, 883-888.	9.4	189
44	International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II. PLoS ONE, 2012, 7, e36438.	1.1	63
45	Journal of AIDS & Clinical Research. Journal of AIDS & Clinical Research, 2012, S8, 3.	0.5	45
46	The direct passage of animal viruses between cells. Current Opinion in Virology, 2011, 1, 396-402.	2.6	68
47	Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen. Vaccine, 2011, 29, 1258-1269.	1.7	37
48	A Novel Strategy for Inducing Enhanced Mucosal HIV-1 Antibody Responses in an Anti-Inflammatory Environment. PLoS ONE, 2011, 6, e15861.	1.1	11
49	Human monoclonal antibodies to HIV-1 gp140 from mice bearing YAC-based human immunoglobulin transloci. Protein Engineering, Design and Selection, 2011, 24, 791-799.	1.0	18
50	Architecture and Regulation of the HIV-1 Assembly and Holding Compartment in Macrophages. Journal of Virology, 2011, 85, 7922-7927.	1.5	47
51	A sweet cleft in HIV's armour. Nature, 2011, 480, 324-325.	13.7	9
52	Reactive Carbonyls Are a Major Th2-Inducing Damage-Associated Molecular Pattern Generated by Oxidative Stress. Journal of Immunology, 2011, 187, 1626-1633.	0.4	53
53	Viral Determinants of HIV-1 Macrophage Tropism. Viruses, 2011, 3, 2255-2279.	1.5	53
54	The Regulated Secretory Pathway in CD4+ T cells Contributes to Human Immunodeficiency Virus Type-1 Cell-to-Cell Spread at the Virological Synapse. PLoS Pathogens, 2011, 7, e1002226.	2.1	65

#	Article	IF	Citations
55	Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals. PLoS ONE, 2010, 5, e8805.	1.1	405
56	Virological Synapse-Mediated Spread of Human Immunodeficiency Virus Type 1 between T Cells Is Sensitive to Entry Inhibition. Journal of Virology, 2010, 84, 3516-3527.	1.5	177
57	SDF-1/CXCL12 Production by Mature Dendritic Cells Inhibits the Propagation of X4-Tropic HIV-1 Isolates at the Dendritic Cell-T-Cell Infectious Synapse. Journal of Virology, 2010, 84, 4341-4351.	1.5	25
58	Retroviruses and the Third Synapse. Viruses, 2010, 2, 1008-1010.	1.5	1
59	Cell-to-Cell Spread of Retroviruses. Viruses, 2010, 2, 1306-1321.	1.5	112
60	Expression-System-Dependent Modulation of HIV-1 Envelope Glycoprotein Antigenicity and Immunogenicity. Journal of Molecular Biology, 2010, 403, 131-147.	2.0	67
61	Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer. Vaccine, 2010, 28, 2482-2489.	1.7	33
62	New templates for HIV-1 antibody-based vaccine design. F1000 Biology Reports, 2010, 2, 60.	4.0	20
63	Re: â€œEnhancement of HIV Infection by Cellulose Sulfate,â€•by Tao et al.. AIDS Research and Human Retroviruses, 2009, 25, 373-373.	0.5	1
64	Candidate Polyanionic Microbicides Inhibit Human T-Cell Lymphotropic Virus Type 1 Receptor Interactions, Cell-Free Infection, and Cell-Cell Spread. Antimicrobial Agents and Chemotherapy, 2009, 53, 678-687.	1.4	14
65	Cell-to-cell HIV-1 spread and its implications for immune evasion. Current Opinion in HIV and AIDS, 2009, 4, 143-149.	1.5	121
66	Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. Nature Cell Biology, 2008, 10, 211-219.	4.6	666
67	HIV's gut feeling. Nature Immunology, 2008, 9, 225-227.	7.0	8
68	Avoiding the void: cell-to-cell spread of human viruses. Nature Reviews Microbiology, 2008, 6, 815-826.	13.6	541
69	EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine, 2008, 26, 3153-3161.	1.7	54
70	Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. Vaccine, 2008, 26, 3346-3351.	1.7	45
71	Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood, 2008, 111, 4660-4663.	0.6	204
72	Correlates of antibody-mediated protection against HIV infection. Current Opinion in HIV and AIDS, 2008, 3, 368-374.	1.5	12

#	Article	IF	Citations
73	Production and Characterization of High-Affinity Human Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Envelope Glycoproteins in a Mouse Model Expressing Human Immunoglobulins. Vaccine Journal, 2007, 14, 157-167.	3.2	5
74	Adhesion Molecule Interactions Facilitate Human Immunodeficiency Virus Type 1-Induced Virological Synapse Formation between T Cells. Journal of Virology, 2007, 81, 13916-13921.	1.5	154
75	Human Immunodeficiency Virus Type 1 Assembly, Budding, and Cell-Cell Spread in T Cells Take Place in Tetraspanin-Enriched Plasma Membrane Domains. Journal of Virology, 2007, 81, 7873-7884.	1.5	167
76	Requirement for an Intact T-Cell Actin and Tubulin Cytoskeleton for Efficient Assembly and Spread of Human Immunodeficiency Virus Type 1. Journal of Virology, 2007, 81, 5547-5560.	1.5	177
77	A functional human IgM response to HIV-1 Env after immunization with NYVAC HIV C. Aids, 2007, 21, 524-527.	1.0	7
78	Regulated secretion from CD4+ T cells. Trends in Immunology, 2007, 28, 474-481.	2.9	34
79	Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides. Antiviral Research, 2007, 75, 188-197.	1.9	33
80	A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nature Medicine, 2006, 12, 905-907.	15.2	187
81	Cryo-Electron Tomographic Structure of an Immunodeficiency Virus Envelope Complex In Situ. PLoS Pathogens, 2006, 2, e83.	2.1	205
82	A Plea for Justice for Jailed Medical Workers. Science, 2006, 314, 924-925.	6.0	3
83	Fundamental Immunology and What it Can Teach us About HIV Vaccine Development. Current Drug Targets Infectious Disorders, 2005, 5, 87-93.	2.1	5
84	The prospects for vaccines against HIV-1: more than a field of long-term nonprogression?. Expert Reviews in Molecular Medicine, 2005, 7, 1-21.	1.6	7
85	Human Immunodeficiency Virus Type 1 Virological Synapse Formation in T Cells Requires Lipid Raft Integrity. Journal of Virology, 2005, 79, 12088-12094.	1.5	125
86	Elimination of Retroviral Infectivity by N -Ethylmaleimide with Preservation of Functional Envelope Glycoproteins. Journal of Virology, 2005, 79, 1533-1542.	1.5	43
87	Interfacial metal and antibody recognition. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14575-14580.	3.3	29
88	V3: HIV's Switch-Hitter. AIDS Research and Human Retroviruses, 2005, 21, 171-189.	0.5	260
89	European Union and EDCTP strategy in the global context: Recommendations for preventive HIV/AIDS vaccines research. Vaccine, 2005, 23, 5551-5556.	1.7	7
90	Heparan Sulfate Targets the HIV-1 Envelope Glycoprotein gp120 Coreceptor Binding Site. Journal of Biological Chemistry, 2005, 280, 21353-21357.	1.6	108

#	Article	IF	Citations
91	Dangerous liaisons at the virological synapse. Journal of Clinical Investigation, 2004, 114, 605-610.	3.9	199
92	HIV-1 Cell to Cell Transfer across an Env-induced, Actin-dependent Synapse. Journal of Experimental Medicine, 2004, 199, 283-293.	4.2	555
93	Retroviral Spread by Induction of Virological Synapses. Traffic, 2004, 5, 643-650.	1.3	201
94	Neutralization of Infectivity of Diverse R5 Clinical Isolates of Human Immunodeficiency Virus Type 1 by gp120-Binding 2â€²F-RNA Aptamers. Journal of Virology, 2003, 77, 12692-12698.	1.5	167
95	Human T-Cell Leukemia Virus Type 1 Envelope Glycoprotein gp46 Interacts with Cell Surface Heparan Sulfate Proteoglycans. Journal of Virology, 2003, 77, 9922-9930.	1.5	93
96	Oligomeric Modeling and Electrostatic Analysis of the gp120 Envelope Glycoprotein of Human Immunodeficiency Virus. Journal of Virology, 2000, 74, 1961-1972.	1.5	248
97	Selective Interactions of Polyanions with Basic Surfaces on Human Immunodeficiency Virus Type 1 gp120. Journal of Virology, 2000, 74, 1948-1960.	1.5	285
98	Antibody neutralization of HIV-1 and the potential for vaccine design. Immunology Letters, 1999, 66, 143-149.	1.1	31
99	HIV-1 attachment: another look. Trends in Microbiology, 1999, 7, 144-149.	3.5	223
100	Cyanovirin-N Binds to gp120 To Interfere with CD4-Dependent Human Immunodeficiency Virus Type 1 Virion Binding, Fusion, and Infectivity but Does Not Affect the CD4 Binding Site on gp120 or Soluble CD4-Induced Conformational Changes in gp120. Journal of Virology, 1999, 73, 4360-4371.	1.5	122
101	Interactions among HIV gp120, CD4, and CXCR4: Dependence on CD4 Expression Level, gp120 Viral Origin, Conservation of the gp120 COOH- and NH2-Termini and V1/V2 and V3 Loops, and Sensitivity to Neutralizing Antibodies. Virology, 1998, 248, 394-405.	1.1	75
102	HIV gp120: double lock strategy foils host defences. Structure, 1998, 6, 945-949.	1.6	33
103	Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 Is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity. Journal of Virology, 1998, 72, 3512-3519.	1.5	182
104	Human Immunodeficiency Virus Type 1 Attachment to HeLa CD4 Cells Is CD4 Independent and gp120 Dependent and Requires Cell Surface Heparans. Journal of Virology, 1998, 72, 3623-3634.	1.5	279
105	CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization. Journal of Virology, 1998, 72, 4694-4703.	1.5	278
106	Inhibition of Virus Attachment to CD4+ Target Cells Is a Major Mechanism of T Cell Lineâ€“adapted HIV-1 Neutralization. Journal of Experimental Medicine, 1997, 186, 1287-1298.	4.2	124
107	HIV-1 antibody â€" debris or virion?. Nature Medicine, 1997, 3, 366-367.	15.2	147
108	HIV infection of primate lymphocytes and conservation of the CD4 receptor. Nature, 1987, 330, 487-489.	13.7	116